Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction.
Hideaki SuzukiTakumi InoueYousuke TeruiKouki TakeuchiKai SusukitaMarina AraiHaruka SatoTaijyu SatohSaori YamamotoNobuhiro YaoitaShunsuke TatebeHideka HayashiKotaro NochiokaHiroyuki TakahamaSatoshi YasudaPublished in: ESC heart failure (2024)
The consistent reduction in PAWP underscores the well-tolerated nature of vericiguat and its potential to enhance cardiac performance in patients with HFrEF.
Keyphrases